Page 432«..1020..431432433434..440450..»

Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas …

By raymumme

This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.

We cordially invite everyone to attend a special open house event at the Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy (RMI) at 801 E. Southlake Blvd. in Southlake, Texas 76092 on Friday, March 6th from 5:30 pm to 7:30 pm. There will be plenty of food, drink and engaging conversation with world-renowned stem cell scientist, Neil H.Riordan, PhD and board-certified orthopedic surgeon, R. Wade McKenna, DO.

Southlake, Texas (PRWEB) March 05, 2015

RMI specializes in Stemnexa non-surgical treatment of acute and chronic orthopedic conditions such as meniscal tears, ACL injuries, rotator cuff injuries, runners knee, tennis elbow, and joint pain due to degenerative conditions like osteoarthritis. Stemnexa may also be administered during orthopedic surgeries to promote better post-surgical outcomes.

Stemnexa combines the latest, patented scientific advances in nearly pain-free bone marrow harvesting with two complimentary cellular technologies: Bone Marrow Aspirate Concentrate (BMAC) and *AlphaGEMS amniotic tissue product.

BMAC contains a patients own mesenchymal stem cells (MSC,) hematopoietic stem cells (CD34+), growth factors and other progenitor cells. AlphaGEMS is composed of collagens and other structural proteins, which provide a biologic matrix that supports angiogenesis, tissue growth and new collagen during tissue regeneration and repair.

*AlphaGEMS product is harvested from donated amniotic sac tissue after normal healthy births. For more information about AlphaGEMS, please visit: http://www.rmiclinic.com/non-surgical-stem-cell-injections-joint-pain/stemnexa-protocol/

Find out more about RMI in the February edition of Society Life Magazine.

Riordan-McKenna Institute

Home

Continue reading here:
Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas ...

To Read More: Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas …
categoriaUncategorized commentoComments Off on Riordan-McKenna Institute of Regenerative Orthopedics and Stem Cell Therapy Announces Open House in Southlake, Texas … | dataMarch 6th, 2015
Read All

Arthritis cure is on the way: Scientists make new breakthrough using embryonic stem cells

By Sykes24Tracey

GETTY

Treatment for the crippling condition is currently limited to basic pain relief or complex joint replacement surgery.

But trials using stem cells have shown astonishing results with tissue almost as good as new after just three months.

Professor Sue Kimber, who led the research, said: This work represents an important step forward in treating cartilage damage using embryonic stem cells to form new tissue.

It may offer a new line of therapy for people with crippling joint pain and we now need this process to be developed for patients.

Osteoarthritis occurs when cartilage at the ends of bones wears away causing severe pain and stiffness.

Researchers say the latest experiments show the procedure could potentially be a safe and effective treatment for more than eight million people who suffer from jointdamage and inflammation.

In the experiments, led by teams at Manchester University and Arthritis Research UK, discarded embryonic stem cells from IVF clinics were transformed into cartilage cells.

These were transplanted into rats with defective joints.

Tests showed the high-quality artificially grown tissue quickly aided the repair of the joint.

See the article here:
Arthritis cure is on the way: Scientists make new breakthrough using embryonic stem cells

To Read More: Arthritis cure is on the way: Scientists make new breakthrough using embryonic stem cells
categoriaSpinal Cord Stem Cells commentoComments Off on Arthritis cure is on the way: Scientists make new breakthrough using embryonic stem cells | dataMarch 4th, 2015
Read All

Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas – Video

By Sykes24Tracey


Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas
Video Testimonial from Glen Wysoki, treated at The STEM CELL THERAPY INSTITUTE of Texas http://stemcellorthopedicinstituteoftexas.com.

By: David Hirsch

View post:
Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video

To Read More: Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas – Video
categoriaUncategorized commentoComments Off on Glen Wysoki at The STEM CELL ORTHOPEDIC INSTITUTE of Texas – Video | dataMarch 4th, 2015
Read All

Procedure Overview – The STEM CELL ORTHOPEDIC INSTITUTE of Texas – Video

By raymumme


Procedure Overview - The STEM CELL ORTHOPEDIC INSTITUTE of Texas
Offering new hope for those in pain, Dr. David Hirsch, D.O., and Dr. John Hall, D. O., of The STEM CELL ORTHOPEDIC INSTITUTE of Texas present an overview of ADULT STEM CELL THERAPY from ...

By: David Hirsch

View post:
Procedure Overview - The STEM CELL ORTHOPEDIC INSTITUTE of Texas - Video

To Read More: Procedure Overview – The STEM CELL ORTHOPEDIC INSTITUTE of Texas – Video
categoriaUncategorized commentoComments Off on Procedure Overview – The STEM CELL ORTHOPEDIC INSTITUTE of Texas – Video | dataMarch 4th, 2015
Read All

'Miraculous' stem cell treatment may reverse symptoms of multiple sclerosis

By Sykes24Tracey

A new stem cell treatment that reboots the entire immune system is enabling multiple sclerosis sufferers to walk, run and even dance again, in results branded "miraculous" by doctors.

Patients who have been wheelchair-bound for 10 years have regained the use of their legs in the ground-breaking therapy, while others who were blind can now see again. The treatment is the first to reverse the symptoms of MS, which is incurable, and affects about 100,000 people in Britain.

The two dozen patients who are taking part in the trials at the Royal Hallamshire Hospital, Sheffield, and Kings College Hospital, London, have effectively had their immune systems "rebooted". Although it is unclear what causes MS, some doctors believe that it is the immune system itself that attacks the brain and spinal cord, leading to inflammation pain, disability and, in severe cases, death.

In the new treatment, specialists use a high dose of chemotherapy to knock out the immune system before rebuilding it with stem cells taken from the patient's own blood. "Since we started treating patients three years ago, some of the results we have seen have been miraculous," Prof Basil Sharrack, a consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, told The Sunday Times.

"This is not a word I would use lightly, but we have seen profound neurological improvements." Holly Drewry, 25, of Sheffield, was wheelchair bound after the birth of her daughter Isla, now two. But she claims the new treatment has transformed her life.

"It worked wonders," she said. "I remember being in the hospital... after three weeks, I called my mum and said: 'I can stand'. We were all crying. I can run a little bit, I can dance. I love dancing, it is silly but I do. " However, specialists warn that patients need to be fit to benefit from the new treatment. "This is not a treatment that is suitable for everybody because it is very aggressive and patients need to be quite fit to withstand the effects of the chemotherapy," warned Prof Sharrack.

The research was published in the Journal of the American Medical Association.

Continue reading here:
'Miraculous' stem cell treatment may reverse symptoms of multiple sclerosis

To Read More: 'Miraculous' stem cell treatment may reverse symptoms of multiple sclerosis
categoriaSpinal Cord Stem Cells commentoComments Off on 'Miraculous' stem cell treatment may reverse symptoms of multiple sclerosis | dataMarch 3rd, 2015
Read All

Full-Body Transplants Are a Crazy, Wildly Unethical Idea

By daniellenierenberg

For the last week, an Italian neurosurgeon has been executing a full-blown media offensive, talking up his plan to stitch one persons head to another persons body. If the powers-that-be would just get over their ethical queasiness, Sergio Canavero of the Turin Advanced Neuromodulation Group says he could accomplish the feat by 2017.

But full-body transplants arent so crazy. In fact, it might surprise you that there was a successful operation as far back as 1818. Well, successful if you ignore that the transplantee freaked out and murdered his doctors family. Oh wait. That was Frankenstein. I take it back, full body transplants are totally crazy.

What the hell, going to the moon was crazy too, right? And a maybe-crazy-but-what-the-hell moonshot is exactly how Canavero sees his plan to help patients with severe physical impairments. Why did the US and the Soviet Union just vie for being the first to space? Because it is about measuring dicks. We want to demonstrate as a country, to say: I am the best, he says. Canaveros latest paper glosses over questions of ethics and practicality and tacklesthe trickiest aspect of the head-swapping procedure: The spinal splice.

Canaveros plan focuses on sewingtwo people together by their spinal cords. (Hooking up the rest of the utilitiesblood vessels, airways, blood vesselsis incredibly difficult, but trifling in comparison.) Step one is to sever the cords with a special, ultra-thin blade. Canavero rightly notes most cases of spinal trauma are well, traumatic: Snapping your neck on a skateboard ramp is bound to leave the spinal cord in an untidy condition. Those nerve cells scar, and scarring would impede their regeneration (if cells in the central nervous system could regeneratewell get to that in a sec). A clean wound, on the other hand, heals cleanly. Canavero likens those million sharply severed neurons to spaghetti. Italians adore spaghetti, I love spaghetti, and spaghetti is what is called for here, he says.

The job of fusing those spaghetti-like spinal sections together falls to a substance called polyethylene glycol. This stuff has actually been pretty good at repairing the motor functions in rats with spinal traumathough even the kindest critic will point out that successful rat experiments are a far cry from proving that the stuff will repair human spines. Still, Canavero is raring to go. I have enough animal data, he says. Give me a brain dead organ donor. Say someone is in a traumatic car accident, and doctors say that he cannot be saved. In the time between when the persons family says its OK to pull the plug and the moment the doctors actually do so, Canavero asks for three to four hours. I sever the spinal cord, add polyethylene glycol, and start measuring electrophysiological responses, he says.

After surgery (and during it, one hopes), Canavero will keep the patient in a coma. He estimates it will take about at least two weeks for the first axons to beginlacing themselves together, at which point the patient can be revived. Throughout the coma and for some time after, Canavero will bathe the spinal splice with a mild electrical current. This is not a free Frankenstein joke from the good doctor: Its actually a method thats seen surprisingly promising results healingrealhuman patients with spinal trauma. Canavero is confident that this will keep the muscle cells operational. Combined with physical therapy, Canavero estimates his as-yet-unchosen patient (any volunteers?) will be back on her (new) feet in about a year.

In case this wasnt entirelyclear: Canaveros plan is insane. Like, James Bond villain insane. And its not just because his plan fits together like a Voltron of bad science (which it does). Its kind of a bummer, actually, because his plan couldmaybework, if he was given free rein to cut and sew living peoples heads to dead peoples bodies until he got it right. But besides ethics, theres an unfortunate fact of biology standing in his way: The central nervous system in higher vertebrateslike humansdoes not regenerate. Hes insane. You cant put a head on somebody else! says Binhai Zhang, a neurosurgeon at UC San Diego. The reason why goes down to your DNA. The genes in a mature mammalian central nervous system that control regeneration are repressed, says Michael Beattie, a professor of neurosurgery at UC San Francisco. Theyll stay that way, no matter how much you treat the spinal cord with polyethylene glycol and electrical currents. (Although, hey, who wants to work on un-repressing those genes?)

Nobody knows for sure why the cells in your brain and spine arent wired for regrowth. After all, your peripheral nervous systemthe circuitry for every other part of your bodyconducts electrical impulses in exactly the same way, but its genes can code for self-repair. Beattie says this may have to do the fact the spine and brain contain the circuitry coded for movement, not just for conducting signals. Spinal cells must knit themselves together in super-complex configurations in order to command the motor functions youve learned over a lifetime. Once the connections are made, you dont want the wrong connections getting created, he says.

The only reliable way to induce spinal cell regrowth in higher order vertebrates is with stem cell therapy. Last year scientists showed pluripotent stem cells could regrow damaged spinal cordsbut only in rats. Mark Tuszynski studies stem cells in spinal injury at UC San Diego, and he says even with this advance the research community is years away from attempting suchtreatments on humans. Its not at the stage yet where there can be meaningful advances in clinical trials, he says. Plus stem cells will need help, in the form of drugs that knock down natural regeneration inhibitors that your body creates (because cancer), and still more drugs to keep your body from creating scar tissue around the wound. (Though in fairness, thats the idea behind Canaveros super-thin knife.) All of this research remainsyears away from clinical application.

And this slow, careful tempodo no harm being a hallmark of western medicineis what drives Canaveros bold assertion that he will have a successful head transplant in 24 months. There are all these people who tell you: Who is this guy who can do this in two years? When you go public with something like this, you have to have two balls like this. There are people who are not so strong-balled and will just get crushed by the critics. But I love the critics. This is a feat of theoretical neuroscience and the evidence is there and its going to work. In case you need clarification, his main argument there is Haters gonna hate.

Excerpt from:
Full-Body Transplants Are a Crazy, Wildly Unethical Idea

To Read More: Full-Body Transplants Are a Crazy, Wildly Unethical Idea
categoriaSpinal Cord Stem Cells commentoComments Off on Full-Body Transplants Are a Crazy, Wildly Unethical Idea | dataMarch 3rd, 2015
Read All

INDERMICA Oxyderm Wrinkle Cream Featured in Elevate Magazine

By LizaAVILA

Greenbrae, CA, March 03, 2015 --(PR.com)-- Oxyderm Wrinkle Cream by INDERMICA Inc. is an innovative skin care product which is free of artificial preservatives; uses innovative apple, grape and alpine rose stem cells to help reverse the signs of aging, helps filling in fine lines while hydrating and smoothing-out skin texture for a youthful glow.

The Patent Pending formula offers the benefits of: -Fast penetration -Cell cleansing by displacing CO2 from the skin -Forehead globular muscular relaxation -Wrinkle reduction and an overall soft-skin feel. The combination of natural ingredients blended with new-age compounds bridge the gap between science and nature.

About Earth Day 2015 Earth Days 45th anniversary (April 22nd) - could be the most exciting year in environmental history. The year in which economic growth and sustainability join hands. This is the year in which world leaders finally pass a binding climate change treaty.

About Elevate Magazine: Elevate Magazine has been Canada's authority on cosmetic enhancement, wellness and anti-aging for over 13 years. Elevate covers every aspect of cosmetic enhancement, offering readers the latest health and beauty news.

About INDERMICA Inc.

INDERMICA Inc. is a manufacturer and global distributor of comprehensive skin restoration professional treatments and take-home systems. The global presence of INDERMICA labs allows them to provide skin-rebuilding formulations that accommodate all skin types throughout the world; committed to creating products that gently return the skin to a young, healthy glow.

Hydroquinone and paraben free; the INDERMICA innovative skin care and treatment products boast a combination of natural ingredients blended with leading-edge compounds. They use a comprehensive and scientific process of layering molecules to prepare, correct and protect damaged and aging skin.

Contact Information: Media Enquiries: Sandra J. Freer comments@sdapublishing.com 416-239-0781 For product information: http://www.indermica.com

Continue reading here:
INDERMICA Oxyderm Wrinkle Cream Featured in Elevate Magazine

To Read More: INDERMICA Oxyderm Wrinkle Cream Featured in Elevate Magazine
categoriaSkin Stem Cells commentoComments Off on INDERMICA Oxyderm Wrinkle Cream Featured in Elevate Magazine | dataMarch 3rd, 2015
Read All

Behind the scenes of the world's first commercial stem-cell therapy

By JoanneRUSSELL25

Contrasto/eyevine

Biologist Graziella Pellegrini has worked on stem-cell therapy at four different Italian institutions, including a hospital run by priests.

Last month saw a major landmark for regenerative medicine: the first time that a stem-cell therapy beside the use of cells extracted from umbilical cords had been cleared for sale by any regulatory agency in the world. The European Commission approved Holoclar for use in cases of blindness caused by burning. The achievement is all the more remarkable because Holoclar was developed by a small laboratory in Italy, a country better known for its lack of support for life sciences and for its recent tolerance of an unproven stem-cell concoction, marketed by the Stamina Foundation, that claimed to be a panacea for many diseases. Nature talked to Graziella Pellegrini from the University of Modena about how she and her colleagues overcame the many obstacles to take the therapy from bench to bedside.

The surface of the cornea the transparent tissue that sits in front of the iris is constantly renewed in a healthy eye, to keep it smooth and clear. New corneal cells are generated from a niche of stem cells in the limbus, an area between the cornea and the white of the eye. But if the limbus is destroyed by burning, then the white of the eye grows over the cornea and becomes criss-crossed with blood vessels. This causes chronic pain and inflammation, as well as blindness.

I had seen patients who had starting seeing again after 20 years of blindness: how could I stop?

Holoclar treatment can help to reverse these symptoms by adding new stem cells to seed the regrowth of a transparent cornea. But there must be enough surviving limbus in one eye to allow 1 or 2 square millimetres of tissue to be extracted. This tissue is then cultivated on a support made from modified human fibrin (a biodegradable blood protein) under stringent clinical conditions until at least 3,000 stem cells have been generated. The culture, still on its fibrin scaffold, is transplanted into the injured eye, which has been scraped clear of the invading white, and from there stem cells seed the regrowth of a transparent cornea, free of blood vessels, within a year.

Only around 1,000 people annually in the whole of Europe will be eligible: burns victims who have become blind but whose eyes have not been too extensively destroyed.

It is always very hard to find research money in Italy. We had to uproot many times. I first started working on the concept of the therapy, with my colleague Michele De Luca, in 1990 when we were post-docs at the University of Genova studying the fundamental biology of epithelial cells the cells that form the sheets lining organs, and also the skin. In 1996, we moved to Rome to the Institute Dermopatico Immaculate, a hospital run by priests who were highly committed to research and who offered us wonderful facilities and access to patients. But in the end they did not want to support our eye work through to the clinic. So in 2002, we moved to the Veneto Eye Bank Foundation in Venice, which had an epithelial stem-cell laboratory. Then in 2008 we moved again, to the Centre for Regenerative Medicine Stefano Ferrari, which had been newly created at the University of Modena specifically to incubate such types of advanced therapy.

Italy is not supportive of biomedical research. Things might have been easier if we had not had to struggle so much. But I am Italian, and the best way to stimulate me to find a solution is to tell me I cant do something. And despite the problems, research into advanced therapies does have a history here. One of the worlds first gene-therapy trials on children with an immunodeficiency disorder was carried out in Milan.

We published the results of our first two patients both successes in 19971. That was proof of principle that the therapy could work. Our major clinical paper, on 112 patients, was published in 20102. Around 77% of the transplants were fully successful, and a further 13% partially successful.

Link:
Behind the scenes of the world's first commercial stem-cell therapy

To Read More: Behind the scenes of the world's first commercial stem-cell therapy
categoriaUncategorized commentoComments Off on Behind the scenes of the world's first commercial stem-cell therapy | dataMarch 3rd, 2015
Read All

Stem cells for life, Life Science Center – Video

By daniellenierenberg


Stem cells for life, Life Science Center

By: Cell Therapy Catapult

Read the original:
Stem cells for life, Life Science Center - Video

To Read More: Stem cells for life, Life Science Center – Video
categoriaUncategorized commentoComments Off on Stem cells for life, Life Science Center – Video | dataMarch 2nd, 2015
Read All

'Miracle' stem cell therapy reverses multiple sclerosis

By daniellenierenberg

In the new treatment, specialists use a high dose of chemotherapy to knock out the immune system before rebuilding it with stem cells taken from the patients own blood.

Stem cells are so effective because they can become any cell in the body based on their environment.

"Since we started treating patients three years ago, some of the results we have seen have been miraculous," Professor Basil Sharrack, a consultant neurologist at Sheffield Teaching Hospitals NHS Foundation Trust, told The Sunday Times.

"This is not a word I would use lightly, but we have seen profound neurological improvements."

During the treatment, the patient's stem cells are harvested and stored. Then doctors use aggressive drugs which are usually given to cancer patients to completely destroy the immune system.

The harvested stem cells are then infused back into the body where they start to grow new red and white blood cells within just two weeks.

Within a month the immune system is back up and running fully and that is when patients begin to notice that they are recovering.

Holly Drewry, 25, of Sheffield, was wheelchair bound after the birth of her daughter Isla, now two.

But she claims the new treatment has transformed her life.

It worked wonders, she said. I remember being in the hospital... after three weeks, I called my mum and said: 'I can stand'. We were all crying.

Follow this link:
'Miracle' stem cell therapy reverses multiple sclerosis

To Read More: 'Miracle' stem cell therapy reverses multiple sclerosis
categoriaUncategorized commentoComments Off on 'Miracle' stem cell therapy reverses multiple sclerosis | dataMarch 1st, 2015
Read All

Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson – Video

By Dr. Matthew Watson


Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson

By: Harry Adelson, N.D.

The rest is here:
Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson - Video

To Read More: Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson – Video
categoriaUncategorized commentoComments Off on Shoulder/Hip torn labrum 2 years and 5 months (respectively) after stem cell therapy by Adelson – Video | dataMarch 1st, 2015
Read All

Study Shows Stem Cells Have Potential to Help Kids Hearts, Too

By Dr. Matthew Watson

Durham, NC (PRWEB) February 27, 2015

Several studies showing the promise of stem cells for treating patients with heart failure have made headline news recently. However, all these studies dealt with adult patients only. New research appearing in this months STEM CELLS Translational Medicine shows that stem cells may have the same potential in treating children with congenital heart diseases that can lead to heart failure.

The study, undertaken by researchers at the Mayo Clinic in Rochester, Minn., looked at the feasibility and long-term safety of injecting autologous umbilical cord blood cells directly into the heart muscle at the pediatric stage of heart development. The study was conducted on pigs, due to their hearts similarity to human hearts.

The team injected the stem cells directly into the right ventricle of groups of three- and four-week old healthy piglets, and then compared the results to a control group that did not receive any cells. Over the next three months, the animals were monitored to assess cardiac performance and rhythm to determine how safe the procedure would be for humans.

During this follow-up period, we found no significant acute or chronic cardiac injury pattern caused by the injections directly into the heart, said lead author Timothy J. Nelson, M.D., Ph.D., of the Mayo Clinics Department of Medicine, and all the animals hearts appeared to be normal and healthy.

This led us to conclude that autologous stem cells from cord blood can be safely collected and surgically delivered to children. The study also establishes the foundation for cell-based therapy for children and aims to accelerate the science toward clinical trials for helping children with congenital heart disease that could benefit from a regenerative medicine strategy, he added.

The lead author, Susan Cantero Peral, M.D., Ph.D. commented, This work highlights the importance and utility of umbilical cord blood as it can be applied to new applications. Rather than discarding this sample at birth, individuals with congenital heart disease may one day be able to have these cells collected and processed in a specialized way to make them available for cardiac regeneration.

This work was funded by the Todd and Karen Wanek Family Program for Hypoplastic Left Heart Syndrome founded at the Mayo Clinic.

These data help establish the foundation of a cell-based therapy for juvenile hearts by showing that injections of autologous cells from cord blood are safe and feasible, said Anthony Atala, M.D., editor of STEM CELLS Translational Medicine and director of the Wake Forest Institute for Regenerative Medicine.

###

See more here:
Study Shows Stem Cells Have Potential to Help Kids Hearts, Too

To Read More: Study Shows Stem Cells Have Potential to Help Kids Hearts, Too
categoriaCardiac Stem Cells commentoComments Off on Study Shows Stem Cells Have Potential to Help Kids Hearts, Too | dataFebruary 28th, 2015
Read All

Quality control for adult stem cell treatment

By NEVAGiles23

A team of European researchers has devised a strategy to ensure that adult epidermal stem cells are safe before they are used as treatments for patients. The approach involves a clonal strategy where stem cells are collected and cultivated, genetically modified and single cells isolated before being rigorously tested to make sure they meet the highest possible safety criteria. The strategy, which is published online in EMBO Molecular Medicine, is inspired by the approaches the biotechnology industry and regulatory affairs authorities have adopted for medicinal proteins produced from genetically engineered mammalian cells.

"Until now there has not been a systematic way to ensure that adult epidermal stem cells meet all the necessary requirements for safety before use as treatments for disease," says EMBO Member Yann Barrandon, Professor at Lausanne University Hospital, the Swiss Federal Institute of Technology in Lausanne and the lead author of the study. "We have devised a single cell strategy that is sufficiently scalable to assess the viability and safety of adult epidermal stem cells using an array of cell and molecular assays before the cells are used directly for the treatment of patients. We have used this strategy in a proof-of-concept study that involves treatment of a patient suffering from recessive dystrophic epidermolysis bullosa, a hereditary condition defined by the absence of type VII collagen which leads to severe blistering of the skin."

The researchers cultivated epidermal cells from the patient that can be used to regenerate skin. The scientists used their array of tests to determine which of the transduced cells met the necessary requirements for stemness -- the characteristics of a stem cell that distinguish it from a regular cells -- and safety. Clonal analysis revealed that the transduced stem cells varied in their ability to produce functional type VII collagen. When the most viable, modified stem cells were selected, transplantation onto immunodeficient mice regenerated skin that did not blister in the mouse model system for recessive dystrophic epidermolysis bullosa and produced functional type VII collagen. Safety was assessed by determining the sites of integration of the viral vector, looking for rearrangements and hit genes, as well as whole genome sequencing.

"Our work shows that at least for adult epidermal stem cells it is possible to use a clonal strategy to deliver a level of safety that cannot be obtained by other gene therapy approaches. A clonal strategy should make it possible to integrate some of the more recent technologies for targeted genome editing that offer more precise ways to change genes in ways that may further benefit the treatment of disease. Further work is in progress in this direction."

Story Source:

The above story is based on materials provided by EMBO - excellence in life sciences. Note: Materials may be edited for content and length.

See more here:
Quality control for adult stem cell treatment

To Read More: Quality control for adult stem cell treatment
categoriaSkin Stem Cells commentoComments Off on Quality control for adult stem cell treatment | dataFebruary 28th, 2015
Read All

Neurons Controlling Appetite Made From Skin Cells

By daniellenierenberg

Contact Information

Available for logged-in reporters only

Newswise NEW YORK, NY (February 27, 2015) Researchers have for the first time successfully converted adult human skin cells into neurons of the type that regulate appetite, providing a patient-specific model for studying the neurophysiology of weight control and testing new therapies for obesity. The study, led by researchers at Columbia University Medical Center (CUMC) and at the New York Stem Cell Foundation (NYSCF), was published last month in the online issue of the Journal of Clinical Investigation.

In a separate study, which appeared in the February 10 issue of the journal Development, Kevin Eggan, PhD, Florian Merkle, and Alexander Schier of Harvard University have also succeeded in creating hypothalamic neurons from iPS cells. These neurons help to regulate behavioral and basic physiological functions in the human body, including, in addition to appetite, hypertension, sleep, mood, and some social disorders. The investigators at Columbia and Harvard shared ideas during the course of the research, and these studies are co-validating.

Mice are a good model for studying obesity in humans, but it would better to have human cells for testing. Unfortunately, the cells that regulate appetite are located in an inaccessible part of the brain, the hypothalamus. So, until now, weve had to make do with a mouse model or with human cells harvested at autopsy. This has greatly limited our ability to study fundamental aspects of human obesity, said senior author Rudolph L. Leibel, MD, the Christopher J. Murphy Memorial Professor of Diabetes Research, professor of pediatrics and medicine, and co-director of the Naomi Berrie Diabetes Center at CUMC.

To make the neurons, human skin cells were first genetically reprogrammed to become induced pluripotent stem (iPS) cells. Like natural stem cells, iPS cells are capable of developing into any kind of adult cell when given a specific set of molecular signals in a specific order. The iPS cell technology has been used to create a variety of adult human cell types, including insulin-producing beta cells and forebrain and motor neurons. But until now, no one has been able to figure out how to convert human iPS cells into hypothalamic neurons, said co-author Dieter Egli, PhD, assistant professor of pediatrics (in developmental cell biology), a member of the Naomi Berrie Diabetes Center, and a senior research fellow at NYSCF.

This is a wonderful example of several institutions coming together to collaborate and advance research in pursuit of new therapeutic interventions. The ability to make this type of neuron brings us one step closer to the development of new treatments for obesity, said Susan L. Solomon, CEO of NYSCF.

The CUMC/NYSCF team determined which signals are needed to transform iPS cells into arcuate hypothalamic neurons, a neuron subtype that regulates appetite. The transformation process took about 30 days. The neurons were found to display key functional properties of mouse arcuate hypothalamic neurons, including the ability to accurately process and secrete specific neuropeptides and to respond to metabolic signals such as insulin and leptin.

We dont think that these neurons are identical to natural hypothalamic neurons, but they are close and will still be useful for studying the neurophysiology of weight control, as well as molecular abnormalities that lead to obesity, said Dr. Leibel. In addition, the cells will allow us to evaluate potential obesity drugs in a way never before possible.

This shows, said Dr. Eggan, how improved understanding of stem cell biology is making an impact on our ability to study, understand, and eventually treat disorders of the nervous system. Because there are so few hypothalamic neurons of a given type, they have been notoriously difficult to study. The successful work by both groups shows that this problem has been cracked.

Original post:
Neurons Controlling Appetite Made From Skin Cells

To Read More: Neurons Controlling Appetite Made From Skin Cells
categoriaIPS Cell Therapy commentoComments Off on Neurons Controlling Appetite Made From Skin Cells | dataFebruary 28th, 2015
Read All

Translational Regenerative Medicine: Market Prospects 2015-2025

By Sykes24Tracey

Report Details

Translational Regenerative Medicine - new study showing you trends, R&D progress, and predicted revenues Where is the market for regenerative medicine heading? What are the commercial prospects for this market and related technologies? Visiongain's brand new report shows you potential revenues and other trends to 2025, discussing data, opportunities and prospects.

Visiongain's report lets you assess regenerative medicine: cell-based therapies that aim to restore function and regenerate diseased tissues. Our 260 page report provides 145 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at world market, submarket and national level. You will see financial results, interviews, trends, opportunities and revenue predictions.

Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces), company profiles and commercial developments. Read the full transcript of an exclusive expert opinion interview from industry specialists informing your understanding and allowing you to assess prospects for investments and sales: Dr Antonio SJ Lee, CEO and Managing Director, MEDIPOST America Inc.

You find prospects for key submarkets and products In addition to analyses of the overall world market, you see revenue forecasts for these three submarkets to 2025: Stem cell therapies Gene Therapies Tissue engineering products

Products that can significantly increase disease-free survival and improve patient tolerance will achieve success. In the long term, we forecast these curative therapies to be adopted by many healthcare systems globally.

Our investigation shows business research and analyses with individual revenue forecasts and discussions. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

See revenue forecasts for products How will leading products perform to 2025 at the world level? Our study forecasts sales of currently marketed and pipeline regenerative medicine products including these: Osteocel Plus Trinity ELITE and Trinity Evolution Prochymal Apligraf Dermagraft ReCell Neovasculgen Glybera Talimogene Laherparepvec (T-Vec)

Discover how high revenues can go. You will see what is happening, understanding trends, challenges and opportunities.

Visit link:
Translational Regenerative Medicine: Market Prospects 2015-2025

To Read More: Translational Regenerative Medicine: Market Prospects 2015-2025
categoriaUncategorized commentoComments Off on Translational Regenerative Medicine: Market Prospects 2015-2025 | dataFebruary 28th, 2015
Read All

Animal cells for a younger you

By JoanneRUSSELL25

THE contemporary age brings a lot of new things that leave people in awe, amazement, and sometimes, in disbelief and disagreement. One thing that the more advanced technology gave birth to is the controversial Stem Cell Therapy (SCT).

According to mayoclinic.org, SCT is the replacement of damaged or diseased stem cells by injecting or infusing healthy stems into your body.

An article from philstar.com also says that SCT replaces or supports ones degenerating tissues and organs. The stem cells used in this technology are capable of developing into different kinds of cells, thus, are also called master cells.

According to bethematch.org, the diseases that are treatable by SCT are leukemia, bone marrow diseases, inherited immune system disorders, and diseases with poorly functioning red blood cells.

SCT is also used as an anti-aging treatment. Some of the prominent Filipinos have used this therapy to maintain their youthful glow and energy.

In the Philippines, clinics offering SCT have sprouted like mushrooms due to its perceived benefits to the patients. In fact, Makati Medical Center has its Cellular Therapeutics Center, equipped with facilities from Germany, USA, and Japan.

In an article from makatimed.net, it was said that the center has an extensive range of services that boast the remarkable efficacy of stem cells.

Dr. Florencio Q. Lucero who started the use of adult SCT in the Philippines in 2006, was quoted in an article from inquirer.net saying that in the Philippines, most of the customers rich businessmen and public officials who are mostly males.

One of them is Manila Mayor Joseph Estrada. He had his SCT at a clinic in Germany called Villa Medica on April 2012. Another article from inquirer.net said that Estrada had 14 shots of blood from the donor animal, the unborn sheep, on his buttocks.

In the same article, Estrada was quoted saying he could sleep better, his knees are working better, and that his skin has shown its glow.

Read the original here:
Animal cells for a younger you

To Read More: Animal cells for a younger you
categoriaUncategorized commentoComments Off on Animal cells for a younger you | dataFebruary 28th, 2015
Read All

Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth

By JoanneRUSSELL25

Albany, NewYork (PRWEB) February 27, 2015

ResearchMoz has announced the addition of a recent study that presents the analysis of the cell culture protein surface coating market across the globe. The research report discusses the current scenario and development prospects of the global cell culture protein surface coating industry for the period of 2015 to 2019.

Read Complete Report With TOC @ http://www.researchmoz.us/global-cell-culture-protein-surface-coating-market-2015-2019-report.html

The research report, titled Global Cell Culture Protein Surface Coating Market, offers an analytical study, providing an in-depth assessment of the industry based on market trends, growth drivers as well as challenges. This is done taking various segments of the market into consideration. The report also forecasts that the worldwide cell culture protein surface coating industry will expand at a CAGR of 12.91% during the forecast period of 2014 to 2019.

Cell culture protein surface coating is defined as the coating process wherein cell culture surfaces are covered with extra-cellular matrix elements or with protein to improve in-vitro linkage and propagation in the cells.

The various kinds of proteins that are available in our surroundings are synthetic proteins, human-derived proteins, plant-derived proteins, and animal-derived proteins. Fibronectin, collagen, laminin, osteopontin, and vitronectin are some of the proteins that are utilized for cell culture protein surface coating. Cell culture protein surface coating assists in the development of several kinds of cells such as epithelial, endothelial, fibroblasts, muscle cells and myoblasts, leukocytes, CHO cell lines, and neurons.

The wide range of applications for cell culture protein surface coatings consist of enhanced adhesion of cells, better propagation and development of cells, cell matrix studies, morphogenesis studies, receptor-ligand binding studies, signal transduction studies, genetic engineering, differentiation of individual cell types, drug screening, and metabolic pathway studies.

Stem cells have high potential for the treatment of severe diseases such as cardiac ailments, neuro degenerative diseases, and even diabetes. This fact has resulted in the increase in demand for highly developed cell culture products for stem cell manufacturing and studies. Cell culture protein surface coating offers enhanced adhesion, propagation, and rapid development of cells during the period of isolation and cultivation.

The main factor that is adding to the growth of the global cell culture protein surface coating industry is increased focus of top market players towards stem cell research. However, the drawbacks of animal-derived protein surface coating is a factor that is soon becoming a matter of concern, hindering the growth of the cell culture protein surface coating market.

Top players of the cell culture protein surface coating industry are EMD Millipore, Thermo Fisher Scientific, Becton, Dickinson and Company, Corning, and Sigma-Aldrich.

See the original post:
Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth

To Read More: Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth
categoriaCardiac Stem Cells commentoComments Off on Global Cell Culture Protein Surface Coating Industry: Rising Focus towards Stem Cells Research to Trigger Market Growth | dataFebruary 27th, 2015
Read All

The Lancet Haematology: Experts warn of stem cell underuse

By LizaAVILA

Since the first experimental bone marrow transplant over 50 years ago, more than one million hematopoietic stem cell transplantations (HSCT) have been performed in 75 countries, according to new research charting the remarkable growth in the worldwide use of HSCT, published in The Lancet Haematology journal.

However, the findings reveal striking variations between countries and regions in the use of this lifesaving procedure and high unmet need due to a chronic shortage of resources and donors that is putting lives at risk.

HSCT (also known as blood and marrow transplant) is most often used to treat diseases of the blood and several types of cancer such as multiple myeloma or leukaemia. For many people with these diseases the only possibility of a cure is to have a HSCT. The procedure provides healthy cells from either the patient (autologous transplantation) or from a healthy donor (allogeneic transplantation) to replace those lost to disease or chemotherapy.

Using data collected by the Worldwide Network for Blood and Marrow Transplantation (WBMT), Professor Dietger Niederwieser from the University Hospital Leipzig in Germany and international colleagues, systematically analysed the growth of HSCT and changes in its use in 194 WHO member countries since the first transplant in 1957. They also examined the link between macroeconomic factors (eg, gross national income and health care expenditure) and transplant frequencies per 10 million inhabitants in each country.

Although only a small number of centres had performed about 10000 transplants by 1985, this had risen to around 500000 ten years later, and doubled to more than 1 million transplants (42% allogeneic and 58% autologous) done at 1516 transplant centres across 75 countries by the end of December 2012 (see table 1 page 2).

Perhaps unsurprisingly, the study found that transplants are more common in countries with greater financial resources and more institutions with the resources and expertise to perform HSCT. Most of the HSCTs have been performed in Europe (53%), followed by the Americas (31%), South East Asia and Western Pacific (15%), and the Eastern Mediterranean and Africa (2%). The findings also reveal significant differences between HSCT use by donor type (autologous or allogeneic), indications for HSCT, and world region (See tables 2, 3, and 4 pages 4-6). For example, donor transplants in 2010 ranged in active countries from 0.4 per 10 million inhabitants in the Philippines and Vietnam to 506 in Israel (see figure 2B page 7).

Numbers of donor transplants have rapidly expanded in all regions without any signs of saturation (see table 1 page 2). This is likely to reflect substantial underuse of this therapy, say the authors, suggesting that more patients would have been treated with allogeneic transplantation had it been accessible, or had suitable donors been available.

In about 30% of cases, a genetically matched donor can be found from within a patient's family. The other 70% have to search for a matched volunteer from national and international registries. The report shows that numbers of countries with registries increased from 2 in 1987 to 57 in 2012, whilst volunteer donors rose from 3072 in 1987 to over 22 million in 2012. The international exchange of stem-cell products also increased to more than 10000 a year between 2006 and 2012, with substantial differences between countries in the amount of stem cells they import or export (see figure 2C page 7).

Despite these increases there are still too many patients who are unable to find a suitable donor. At any time around 1800 people in the UK are waiting for a blood stem cell donation, and over 37000 people are waiting worldwide. Moreover, less than half of the people in the UK diagnosed with a blood cancer ever find a suitable donor [1].

According to Professor Niederwieser, "Patients, many of them children, are facing a life and death situation. Ultimately they will die if they cannot get the treatment they need. All countries need to provide adequate infrastructure for patients and donors to make sure that everyone who needs a transplant gets one, rather than the present situation in which access remains restricted to countries and people with sufficient resources."[2]

Link:
The Lancet Haematology: Experts warn of stem cell underuse

To Read More: The Lancet Haematology: Experts warn of stem cell underuse
categoriaBone Marrow Stem Cells commentoComments Off on The Lancet Haematology: Experts warn of stem cell underuse | dataFebruary 27th, 2015
Read All

Growth signal can influence cancer cells' vulnerability to drugs, study suggests

By NEVAGiles23

Exposure to TGF-beta prompts changes that help mouse tumor stem cells evade drugs

IMAGE:To see how the growth signal TGF-beta influences cancer cells, the researchers used a red tag (top) to mark mouse tumor stem cells that received the signal, and a green... view more

Credit: Laboratory of Mammalian Cell Biology and Development

In theory, a tumor is an army of clones, made up of many copies of the original cancerous cell. But tumor cells don't always act like duplicates, and their unpredictable behavior can create problems for treatment. For while some cells within a tumor succumb to anti-cancer drugs, others may survive to bring the cancer back to life once therapy has ended.

In a study published today (February 26) in Cell, researchers at Rockefeller University home in on one culprit that fuels this variable vulnerability within squamous cell cancers: exposure to a signal known as TGF-, given off by immune cells that congregate next to a tumor's blood vessels.

"There are several reasons why some cancer stem cells, the cells at the root of tumors and metastases, can withstand therapy meant to eradicate them. Our results point to the importance of the environment immediately surrounding the skin cancer stem cells, specifically, their exposure to the signal TGF-," says senior researcher Elaine Fuchs, Rebecca C. Lancefield Professor, head of the Robin Chemers Neustein Laboratory of Mammalian Cell Biology and Development and a Howard Hughes Medical Institute investigator. "Ultimately, we hope this new insight could lead to better means for preventing the recurrence of these life-threatening cancers, which can occur in the skin, head, neck, esophagus, and lung, and often evade treatment."

Her team, which included first author Naoki Oshimori, a postdoctoral research associate in the lab and lab technician Daniel Oristian, focused on squamous cell carcinomas in the skin of mice. Like many normal tissue stem cells, the stem cells that produce squamous cell tumors can be classified into two types: those that divide and proliferate rapidly, and those that do so more slowly. This has led scientists to wonder whether the more dormant stem cells in a tumor might evade cancer drugs.

To investigate this possibility, the team zeroed in on TGF- (transforming growth factor beta) which is known to restrict growth in many healthy tissues. The lab's previous research has shown that mice whose normal skin stem cells cannot respond to TGF- become susceptible to develop tumors that grow rapidly. Paradoxically, however, TGF- contributes to metastasis in many cancers. The researchers wanted to know: How can TGF- act both to suppress cancers and promote them?

By visualizing TGF- signaling within developing mouse tumors, the researchers found that the cancer stem cells located nearest to the blood vessels of the tumor receive a strong TGF- signal, while others further away don't receive any. To see this difference and its effects, they used a red tag to illuminate those cells exposed and responding to TGF-, and a green genetic tag, which they could switch on, to track the stem cells' progeny. Over time, they saw that TGF--responding stem cells proliferate more slowly but they simultaneously invade, scatter and move away from the tumor. The opposite was true of cancer stem cells too far away to receive TGF-, which proliferated rapidly, but were less invasive, growing as a tumor mass.

"We tested the implications for drug resistance by injecting cisplatin, a commonly used chemotherapy drug for these types of cancers, into the mice with tumors. While the drug killed off most of the TGF- nonresponding cancer cells, it left behind many of the responders," Oshimori says. "When the drug was withdrawn, the lingering TGF- responding cancer stem cells grew back the tumor."

More here:
Growth signal can influence cancer cells' vulnerability to drugs, study suggests

To Read More: Growth signal can influence cancer cells' vulnerability to drugs, study suggests
categoriaSkin Stem Cells commentoComments Off on Growth signal can influence cancer cells' vulnerability to drugs, study suggests | dataFebruary 27th, 2015
Read All

Graphene derivative interferes with seemingly invincible cancer stem cells

By LizaAVILA

While well known for its unique electromechanical properties, graphene may also prove key in preventing cancer tumor recurrence. A drawback of traditional cancer treatment with radiation and chemotherapy is that the primary developmental source of future tumors is not eradicated. Cancer stem cells, or CSCs, can survive treatment and give rise to recurring tumors, metatasis, and drug resistance after repeated treatments. Researchers from the University of Manchester and the University of Calabria have discovered that graphene oxides targets and neutralize CSCs in a manner that is not yet fully understood.

One CSC can develop into a ball of new CSCs called a tumor-sphere, or into new tumor cells, such as what happens in metastasis. They're immortal, divide rapidly, and resist stress. A potential solution? Graphene oxide, GO, which is an oxidized form of its well-known carbon cousin and soluble in many solvents.

For a complete look at the efficacy of GO across cancers, researchers used CSCs from six types of cancer: breast, pancreatic, lung, brain, ovarian and prostate. They also used normal skin cells to confirm that GO would not be toxic to the body.

After cells were treated for 48 hours with a GO solution, the researchers found that not only did GO interrupt the ability of CSCs in all cancer types to proliferate by forming spheres, but that GO was safe to the skin cells.

Dr Aravind Vijayaraghavan of the National Graphene Institute at the University of Manchester says that GO seems to force the cancer stem cells to differentiate into non-cancer stem cells. In this way, GO effectively takes the CSC out of commission for creating future tumors. Currently the theory is that GO interferes with the signalling pathways in the cell membranes, curbing the proliferation mechanism.

Interestingly, this graphene derivative had already been researched for as a targeted delivery vehicle in tumors, but has now been found to have an important effect itself on the tumor.

While the researchers acknowledge that the mechanisms at play need to be researched more before the material can be used to treat cancers, the ability to destroy cancer stem cells is an an important component of a cancer treatment protocol that kills existing tumors as well as shuts down future metatasis.

Vijayaraghavan and the Graphene Institute have previously made headlines as a recipient of research money from the Bill and Melinda Gates Foundation towards the development of a better condom. Their proposal, of course, used graphene.

The team's research was originally published in Oncotarget on February 24, 2015.

Source: University of Manchester

See the original post:
Graphene derivative interferes with seemingly invincible cancer stem cells

To Read More: Graphene derivative interferes with seemingly invincible cancer stem cells
categoriaSkin Stem Cells commentoComments Off on Graphene derivative interferes with seemingly invincible cancer stem cells | dataFebruary 27th, 2015
Read All

Page 432«..1020..431432433434..440450..»


Copyright :: 2024